MedTrace Logo

Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

NCT05575440 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2026-02-27

No results posted yet for this study

Summary

This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET/CT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.

Conditions

  • Differentiated Thyroid Gland Carcinoma
  • Thyroid Gland Follicular Carcinoma
  • Thyroid Gland Papillary Carcinoma

Interventions

PROCEDURE

Computed Tomography

Undergo a PET/CT scan

RADIATION

Fluorine F 18 Tetrafluoroborate

Given IV

PROCEDURE

Positron Emission Tomography

Undergo a PET/CT scan

OTHER

Survey Administration

Ancillary studies

Sponsors & Collaborators

Principal Investigators

  • Stephen M. Broski, M.D. · Mayo Clinic in Rochester

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-22
Primary Completion
2028-05-01
Completion
2028-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05575440 on ClinicalTrials.gov